Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session: Supportive and palliative care

1263O - Evaluation of weight gain and overall survival of male vs. female patients with advanced non-small cell lung cancer (NSCLC) receiving first-line chemotherapy

Date

11 Sep 2022

Session

Proffered Paper session: Supportive and palliative care

Topics

Supportive Care and Symptom Management

Tumour Site

Thoracic Malignancies

Presenters

Eric Roeland

Citation

Annals of Oncology (2022) 33 (suppl_7): S581-S591. 10.1016/annonc/annonc1066

Authors

E.J. Roeland1, F.J. Fintelmann2, R. Yang3, L.C. Tarasenko4, T.D. McRae5, J.H. Revkin6, P.D. Bonomi7

Author affiliations

  • 1 Knight Cancer Institute, Oregon Health and Science University, 97239 - Portland/US
  • 2 Cancer Center, Massachusetts General Hospital, 02114 - Boston/US
  • 3 Biostatistics, Pfizer Inc, 10017 - New York/US
  • 4 Global Medical Affairs, Pfizer Inc, 10017 - New York/US
  • 5 Internal Medicine Business Unit, Global Product Development, Pfizer Inc, 10017 - New York/US
  • 6 Internal Medicine Research Unit, Clinical Development, Pfizer Inc, 02139 - Cambridge/US
  • 7 Department Of Internal Medicine, Division Of Hematology, Oncology And Cell Therapy, Rush University Medical Center, 60612 - Chicago/US
More

Resources

Login to access the resources on OncologyPRO.

Abstract 1263O

Background

Cancer cachexia is a multifactorial syndrome characterized by anorexia and unintentional weight loss associated with poor clinical outcomes. Conversely, weight gain during cancer treatment may improve survival. The objective of this post-hoc analysis was to examine the relationship between sex, weight gain, and overall survival (OS) in patients with advanced lung cancer receiving standard-of-care (SOC) chemotherapy.

Methods

Data were pooled from three phase III clinical trials (NCT00254891, NCT00254904, NCT00596830) conducted between Nov 2005 and Mar 2011 in patients with advanced (stage IIIB/IV) NSCLC treated with first-line SOC chemotherapy (control arm). Weight was recorded at baseline, day 1 of each 3-week treatment cycle (up to 6 cycles), and after treatment per each study’s schedule. Weight gain was categorized as >0%, >2.5%, and >5% increase from baseline up to 4.5 months after chemotherapy initiation. The Kaplan-Meier method was used to estimate each subgroup's survival and median survival.

Results

The total 1,030 patients were predominantly male (70.5%) with stage IV NSCLC (88.4% male and 88.8% female). The median age (range) of male and female patients was 62 (34-87) and 60 (34-83) years, while the mean BMI (SD) was 24.5 (4.2) and 24.8 (4.8) kg/m2, respectively. Most patients were current/previous smokers (94.2% male and 67.4% female). Overall, 486 (46.1% male vs. 49.7% female), 299 (29.6% vs. 27.6%), and 164 (17.2% vs. 12.8%) patients experienced weight gain from baseline of >0%, >2.5%, and >5%, respectively. Weight gain was associated with a significant decrease in the risk of death in both sexes (Table). The interaction test showed no significant difference in the association between weight gain and increased survival in males vs. females. Table: 1263O

OS hazard ratios (95% CI) associated with weight gain in male and female patients

Weight Categories Male (n = 726) Female (n = 304)
n HR (95% CI) n HR (95% CI)
>0% 335 0.60 (0.50, 0.71) 151 0.65 (0.49, 0.86)
>2.5% 215 0.57 (0.47, 0.70) 84 0.61 (0.44, 0.86)
>5.0% 125 0.62 (0.49, 0.79) 39 0.69 (0.43, 1.09)

Conclusions

The beneficial effect of weight gain on OS was observed regardless of sex in advanced NSCLC patients.

Clinical trial identification

NCT00254891, NCT00254904, NCT00596830.

Editorial acknowledgement

Medical writing support was provided by Diane Hoffman, PhD, of Engage Scientific Solutions and was funded by Pfizer.

Legal entity responsible for the study

Pfizer Inc.

Funding

Pfizer Inc.

Disclosure

E.J. Roeland: Financial Interests, Personal, Advisory Board: Care4ward, Actimed Therapeutics, Meter Health, Napo Pharmaceuticals, Alerion, Takeda; Financial Interests, Personal, Advisory Role: Veloxis Therapeutics, BOYMass; Financial Interests, Personal, Data Monitoring Committee: Enzychem Lifesciences Pharmaceutical Company. R. Yang: Financial Interests, Personal, Full or part-time Employment: Pfizer; Financial Interests, Personal, Stocks/Shares: Pfizer. L.C. Tarasenko: Financial Interests, Personal, Full or part-time Employment: Pfizer; Financial Interests, Personal, Stocks/Shares: Pfizer. T.D. McRae: Financial Interests, Personal, Full or part-time Employment: Pfizer; Financial Interests, Personal, Stocks/Shares: Pfizer. J.H. Revkin: Financial Interests, Personal, Full or part-time Employment: Pfizer; Financial Interests, Personal, Stocks/Shares: Pfizer. P.D. Bonomi: Financial Interests, Personal, Advisory Role: Merck, Pfizer, Roche Genentech. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.